CLINICAL TRIAL SOLUTIONS
How can we support you?
Explore our Phase II-III CRO Services
PharPoint works diligently to help clients plan, manage, and analyze effective Phase II-III clinical trials. Whether you are looking for individual service support or looking to fully outsource your trial operations, our team is happy to chat.
THE PHARPOINT DIFFERENCE
Helping sponsors meet their Phase II and Phase III study goals
AN EXPERIENCED TEAM
For Phase II-III Success
PharPoint aligns sponsors with teammates that have the right knowledge and experience to proactively identify factors critical to study success and mitigate potential study challenges. Working with the PharPoint team also means clear communication pathways and access to senior resources.
WORK COLLABORATIVELY
with a team that works without silos
From the start, the PharPoint team works collaboratively across functions to ensure study decisions are made with input from multiple perspectives. This connected approach helps us better anticipate challenges, accelerate timelines, and support deliverables that have our clients end goals in mind.
GET RESULTS FASTER
with PharPoint’s Industry-Best Biometrics Timelines
At every step, PharPoint’s standard biometrics CRO timelines are industry-best. Throughout your study, clean data are soft locked, reducing the number of subjects needing to be locked following Last Participant, Last Visit (LPLV) and decreasing the timeline to database lock to only 5 days after final Source Document Verification (SDV).
Explore Related Resources
Database Build: Our Standard Timeline from Final Protocol to Database Go-Live
How long does it take to go from final protocol to database go-live?
Examining Strategies for Faster Clinical Study Report Timelines
Examining Strategies for Faster Clinical Study Report Timelines How long does it take a medical writer to produce a high-quality clinical study report (CSR)? What can a medical writer do to help speed up this turnaround without sacrificing quality? Biopharma companies are under increased pressure to reduce timelines, yet this acceleration cannot come at the expense of accuracy or regulatory compliance. JUMP TO: What is the standard timeline for CSR delivery? Strategies to accelerate CSR timelines responsibly Multiple writers QC processes Peer review Draft data We spoke with PharPoint’s Associate Director of Medical Writing, Samia Khader, to discuss her thoughts on potential strategies for the faster delivery of a final CSR. Evaluating the standard timeline for CSR delivery CSR timelines can vary greatly depending on a range of factors which are not all under a medical writer’s control. That said, according the American Medical Writers Association, a common timeline for the delivery of a CSR is about 52-60 working days. At PharPoint, our typical timeline from receipt of final Tables, Listings, and Figures (TLFs) to the delivery of a final CSR is 40 business days. This includes two rounds of review, with drafts reviewed by Sponsors within five business days. PharPoint Standard CSR Timeline What strategies might a medical writer use to accelerate CSR timelines responsibly? Responsible acceleration of the CSR timeline requires deliberate process choices that can improve coordination and reduce inefficiencies while protecting quality and compliance of the final deliverable. In the sections below, we outline several ways that a medical writer might help move a CSR forward, along with a verdict on each approach and the conditions where it makes sense (or does not). Using multiple writers There are circumstances where using multiple medical writers might provide meaningful acceleration, however, strategic planning and coordination is required for
Solving Data Management Challenges with Strategic CRO Oversight
Explore three common findings from a data management consultant who has experience performing DM CRO oversight.
Achieving Expedited Database Lock with Director of DM, Wendy Moffett
Director of Data Management Wendy Moffett discusses how PharPoint achieves rapid database lock in this short video.
A Guide to Reviewing Regulatory Documents as a Subject Matter Expert (SME)
We discuss best practices to allow a reviewer to effectively and efficiently provide critical input to regulatory documents.
Four Signs It is Time to Break Up with Your Regulatory Medical Writing Vendor
Explore some of the standards should you expect from your regulatory medical writing partner.
